EOLS Key Statistics, Chart & Performance
The current stock price of EOLS is 6.85 USD. In the past month the price decreased by -1.86%. In the past year, price decreased by -38.23%.
EOLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About EOLS
Company Profile
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 329 full-time employees. The company went IPO on 2018-02-08. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Company Info
EVOLUS INC
520 Newport Center Dr Ste 1200
Newport Beach CALIFORNIA 92660 US
CEO: David Moatazedi
Employees: 329
Phone: 19492844555
EVOLUS INC / EOLS FAQ
What does EVOLUS INC do?
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 329 full-time employees. The company went IPO on 2018-02-08. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Can you provide the latest stock price for EVOLUS INC?
The current stock price of EOLS is 6.85 USD. The price increased by 0.59% in the last trading session.
What is the dividend status of EVOLUS INC?
EOLS does not pay a dividend.
What is the ChartMill rating of EVOLUS INC stock?
EOLS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for EOLS stock?
EVOLUS INC (EOLS) currently has 329 employees.
What is EVOLUS INC worth?
EVOLUS INC (EOLS) has a market capitalization of 444.02M USD. This makes EOLS a Small Cap stock.
EOLS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EOLS. When comparing the yearly performance of all stocks, EOLS is a bad performer in the overall market: 79.16% of all stocks are doing better.
EOLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EOLS. EOLS has a bad profitability rating. Also its financial health evaluation is rather negative.
EOLS Financial Highlights
Over the last trailing twelve months EOLS reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -9.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.74% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EOLS Forecast & Estimates
For the next year, analysts expect an EPS growth of -81.56% and a revenue growth 12.13% for EOLS